VICTORION-INITIATE – Comparing Inclisiran First to Usual Care in Patients with ASCVD

Please watch below for Important Safety Information and Indication, and please see full Prescribing Information here: https://qr.qrhub.ly/LEQVIO-PI | LEQVIO® (inclisiran) HCP

Nuovo studio italiano conferma efficacia Inclisiran con una riduzione del colesterolo LDL del 60%

Who Is Appropriate for PCSK-9 Inhibitors, Including Inclisiran?

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Inclisiran for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease

Nuovo studio italiano conferma efficacia Inclisiran con una riduzione del colesterolo LDL del 60%

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol (ORION-3)

Non-Statin Therapies for Elevated LDL-C: The Role of Inclisiran (and Other Therapeutics)